Phaseline

Targets › ELAVL1

ELAVL1 (ELAV-like protein 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability. Involved in embryonic stem cell (ESC) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESC differentiation (By similarity). (UniProt, Q15717)

Open in Phaseline: the race on ELAVL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Degron TherapeuticsDEG6498
molecular glue inducing HuR (human antigen R) degradation
ELAVL1Phase 1Malignant NeoplasmsDec 2028

Conditions

Malignant Neoplasms (1)

Modalities

small molecule (1)

Companies

Degron Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.